

## Molecular modeling of interaction between $\delta$ opioid receptor and 3-methylfentanylisothiocyanate<sup>1</sup>

RONG Suo-Bao, JIANG Hua-Liang, CHI Zhi-Qiang, CHEN Kai-Xian, ZHU You-Cheng, JI Ru-Yun  
(Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200031, China)

**KEY WORDS** delta opioid receptors; molecular models; binding sites; ligands; fentanyl

**AIM:** To construct a 3D structural model of  $\delta$  opioid receptor ( $\delta$ OR) and study its interaction with 3-methylfentanylisothiocyanate (SuperFIT).


**METHODS:** Using the bacteriorhodopsin as a template, the 3D structure of  $\delta$ OR was modeled; SuperFIT was docked into its inside. **RESULTS:** The interaction model between  $\delta$ OR and (3R,4S)-SuperFIT was achieved, in which the important binding sites possibly were Asp128, Ser106, Phe104, Tyr308, and Pro315. Asp128 formed the electrostatic and hydrogen-binding interactions with the protonated nitrogen on piperidine of the ligand. Ser106 formed the electrostatic interaction with the N atom of isothiocyanate group of the ligand; whereas Phe104, Tyr308, and Pro315 formed the hydrophobic interactions with the S atom of isothiocyanate group. In addition, there were some other interactions between  $\delta$ OR and the ligand. **CONCLUSION:** The residues Phe104, Tyr308, Pro315, and Ser106 of  $\delta$ OR are crucial to the  $\delta$  selectivity of the ligand, which is beneficial for designing novel  $\delta$ -selective ligand.

Fentanylisothiocyanate (FIT), 4 stereoisomers of 3-methylfentanylisothiocyanate (SuperFIT) and 8 stereoisomers of ohmfentanylisothiocyanate (OMFIT) were synthesized in our laboratory<sup>[1]</sup>. The preliminary pharmacological studies<sup>[1]</sup> revealed that their selectivity for  $\delta$ OR obviously increased, comparing to fentanyl, 4 stereoisomers of 3-methylfentanyl (3-MF) and 8 stereoisomers of ohmfentanyl.

The amino acid sequence of  $\delta$ OR had been determined from its cDNA sequence<sup>[2]</sup>, which belongs to the G protein-coupled receptor (GPCR)

family and contains 7 transmembrane (TM) segments, presumably adopting an  $\alpha$ -helical conformation. The  $\delta$ OR consists of 372 amino acid residues and the N-terminal is in the extracellular space, the C-terminal the intracellular.

In this paper, to investigate the interaction of  $\delta$ OR with SuperFIT and explain the selectivity of SuperFIT for  $\delta$ OR, we have applied computer-aided model building techniques to generate 3D structural model of  $\delta$ OR.



(3R,4S)-SuperFIT

### METHODS

Molecular modeling and display were performed with the molecular modeling package SYBYL 6.2<sup>[3]</sup> on SGI XZ 4000 workstation.

The 7 putative TM segments<sup>[2]</sup> were transformed into  $\alpha$ -helical conformations with the normal  $\varphi$  and  $\psi$  values of  $-58^\circ$  and  $-47^\circ$ , but proline residue with  $\varphi -75^\circ$ , which caused kinks in the helices. The arrangement of 7 helices of  $\delta$ OR was modeled using the structure of bacteriorhodopsin (bRh) as a template, in which the alignment between  $\delta$ OR and bRh was achieved on the basis of Sander's method<sup>[4]</sup>. The refined structure of bRh was read from the Protein Data Bank (PDB, entry 1BRD)<sup>[5]</sup>.

The geometry of the receptor was optimized with the conjugate gradient minimizer until the RMS energy gradient  $<0.7 \text{ kcal} \cdot \text{mol}^{-1} \cdot \text{nm}^{-1}$ , in which the other parameters were a distance-dependent dielectric constant of 5.0, nonbonded cut off of 0.8 nm and AMBER force field with Kollman all-atom charges. The all sidechains of 7 helices with fixed backbone were minimized to convergence; then, the whole receptor to convergence.

(3R,4S)-SuperFIT was docked into the possible binding sites in the 7 helix bundles of  $\delta$ OR. To obtain the better

<sup>1</sup> Project supported by the National Natural Science Foundation of China, No 39470805.

Received 1996-09-03

Accepted 1997-01-28

interaction model, the docking procedure was repeated 5 times by manually adjusting various starting orientations of the ligand. The ligand-receptor complex was optimized using Tripos force field with Kollman all-atom charges for the receptor and Gasteiger-Huckel charges for the ligand.

**RESULTS AND DISCUSSION**


**Modeling of  $\delta$ OR** As the feature of  $\delta$ OR is common to all GPCR and some residues are conserved in all GPCR, it is expected that these receptors have similar 3D architecture. However, no 3D structure has been determined for any of the GPCR.

The 3D structure of bRh, as well as the arrangement of its helices and the position of side chains had been determined by electron cryo-microscopy<sup>[5]</sup>. Although there is little sequence homology between bRh and visual rhodopsin, a number of GPCR family, both proteins consist of 7 TM segments and bond a retinal molecule at a lysine residue in TM7. They are activated by light with *cis-trans* isomerization of retinal<sup>[6]</sup>. It seems reasonable to assume that visual rhodopsin and other GPCR, including  $\delta$ OR, have a helix arrangement similar to that of bRh. This assumption was the foundation of modeling 3D structure of  $\delta$ OR in this study.

According to Sander's method<sup>[4]</sup>, when threading a putative TM segment of the receptor through a bRh helix and shifting its sequence  $\pm 8$  position related to the original alignment (shift = 0), the plot of the sums of residue environmental preferences vs threading shift was obtained for each TM segment of  $\delta$ OR, all of which are plotted in Fig 1.

Theoretically, the alignment with the highest score should be chosen. But, the alignment is complicated. So, the several alignments with higher score were applied to the attemptation of modeling  $\delta$ OR. In this way, the final sequence alignments of TM segments between  $\delta$ OR and bRh were selected as Fig 2.

After energy minimization, the 3D structural model of  $\delta$ OR was achieved. In this model, the nonaromatic hydrophobic residues were mainly on the lipid-facing surface of the receptor; whereas the conserved and polar residues chiefly on the inside



**Fig 1.** Scores when threading  $\delta$ OR sequence through bRh structure vs threading shift. A) TM1 (○), TM2 (●), TM3 (×), and TM4 (□) are the threading shift of 0, 4, -1, and 2, respectively. B) TM5 (○), TM6 (●), and TM7 (×) are the threading shift of 3, 0, and 3, respectively.

TM1	bRh	11	IWLALGTALMGLGTLFLVVKGM	32
	$\delta$ OR	52	ITALYSAVCAVGLLGNVLVMFG	73
TM2	bRh	38	DAKKFYAITTLVPAIAFTMYLSML	61
	$\delta$ OR	88	IFNLALADALATSTLPEQSAKYLK	111
TM3	bRh	81	ARYADWLFETPLLLDLALL	100
	$\delta$ OR	123	AVLSIDYINMETSIFTLTMM	142
TM4	bRh	108	LLALVGADGIMIGTGLVGL	127
	$\delta$ OR	167	LINICIVFLASGVVPIVMV	186
TM5	bRh	137	FWAISTAAMLYILVLFEGST	157
	$\delta$ OR	215	ICVELFAFVVPILITVCYGL	235
TM6	bRh	167	VASTFKVLRNVTVVLWSAYPV	187
	$\delta$ OR	261	VLVVVGAFFVVCWAPIHIFVIV	283
TM7	bRh	204	ETLLEFMVLDVSAKVGFLI	222
	$\delta$ OR	303	CIALGYANSSLNEVLYAFL	321

**Fig 2.** Alignment of TM regions of bRh and  $\delta$ OR. The underlined alphabets represent the binding sites, the double underlined are the key residues for  $\delta$ -selectivity of (3R,4S)-SuperFIT.

surface of the 7 helix bundles, which is accordant with the helical arrangement of GPCR<sup>[7]</sup>.

In the present modeling, loop regions connecting individual helices were omitted, because it was difficult to predict their conformation.

However, omission of the loop regions was not a big problem in the analysis of the receptor-ligand interaction as the ligand-binding sites was supposed to be located in the intra-TM region<sup>(8)</sup>.

#### Modeling of (3R,4S)-SuperFIT- $\delta$ OR complex

In the above  $\delta$ OR model, there were 3 charged residues in TM region, *ie*, two negatively charged residues (Asp95 and Asp128) and one positively charged residue (His278). Of these amino acid residues, 2 Asp residues were conserved with all GPCR<sup>(9)</sup>. The Asp128 mutants decreased affinities of all agonists<sup>(10)</sup>. So, the residue Asp128 would be chosen as the binding site of the protonated nitrogen on piperidine of the ligand. Meanwhile, we considered that the positively charged residue His278, to some extent, probably interacted with the negatively charged carbonyl oxygen of the ligand.

In this way, the protonated (3R, 4S)-SuperFIT was docked into the cavity of 7 helix bundles. The bioactive conformation used in docking was selected as the common conformation of FIT, 4 stereoisomers of SuperFIT and 8 stereoisomers of OMFIT, which was attained by multi-conformational search and DISCO method. Undergoing manual adjustment, the docking procedure was carried out to convergence. The geometric optimization of the ligand-receptor complex was also performed to convergence. The 3D complex model of  $\delta$ OR with (3R,4S)-SuperFIT was achieved (Fig 3).

In the model, the possible binding sites could be the following amino acids (Fig 4): Asp128 (TM3), His278 (TM6), Tyr129 (TM3), Trp173 (TM4), Ser106 (TM2), Phe104 (TM2), Tyr308 (TM7), and Pro315 (TM7).

The negatively charged oxygen of Asp128 formed the potent electrostatic and hydrogen-binding interactions with the positively charged ammonium group on piperidine of SuperFIT. Comparatively, these interactions between His278 and the carbonyl oxygen in 4-phenylpropanamide of the ligand became exceedingly weaker, because the conformation of 4-phenylpropanamide of the ligand led to ligand's carbonyl oxygen far away from His278. There took place some other interactions between  $\delta$ OR and the ligand:




Fig 3. Stereoview of  $\delta$ OR with (3R,4S)-SuperFIT docked at binding sites. Only 2 residues (Asp128 and His278) and the trace of the main chain are displayed. (A) Top view; (B) Side view.


(1) Ser106 bound with the N atom of isothiocyanato group of SuperFIT through the electrostatic interaction.

(2) Phe104, Tyr308, and Pro315, which could form one small hydrophobic pocket, might be occupied by the S termini of isothiocyanato group of the ligand through hydrophobic interaction.


(3) Leu125, Tyr129, and Val181 would also form another small hydrophobic pocket, which might be accommodated by 3-methyl of SuperFIT and resulted in the hydrophobic interaction with the ligand.

(4) Tyr129 and Trp173 formed the very weak  $\pi-\pi$  interactions with the phenyl ring in 4-phenylpropanamide of the ligand, because this phenyl ring escaped from the middle of Tyr129 and Trp173.


**Ligand's key moieties and bioactive conformation** From the (3R,4S)-SuperFIT- $\delta$ OR complex model, it was obvious that the ligand's key



(A)  $\delta$ OR-(3R,4S)-SuperFIT complex model



(B)  $\mu$ OR-(3R,4S)-3-MF complex model



(C)  $\mu$ OR-(3R,4S)-SuperFIT complex model.

Fig 4. The ligand-binding sites.

moieties for interacting with  $\delta$ OR included isothiocyano group, nitrogen atom on piperidine, the carbonyl oxygen and the phenyl ring of 4-propanamide. These moieties are meaningful for us to study 3 dimensional quantitative structure-activity relationship of (3R,4S)-SuperFIT derivatives using comparative molecular field analysis method.

We extracted (3R,4S)-SuperFIT from complex model, keeping ligand's conformation fixed, and compared this bioactive conformation

with the initial conformation used in docking. We also made systematic conformational search for (3R,4S)-SuperFIT extracted from the complex model, in which the nitrogen atom and 4-carbon atom on piperidine of the ligand kept fixed, and docked each conformation into  $\delta$ OR model. This method was named Sys-Docking, in which the binding energy ( $E_{binding}$ ) of the  $\delta$ OR complex with each conformation was calculated according to the following equation.

$$E_{binding} = E_{complex} - E_{ligand} - E_{receptor}$$

In this way, the complex model with the lowest  $E_{binding}$  was obtained, in which the ligand's conformation could be the extremely reasonable bioactive conformation. The bioactive conformations of (3R,4S)-SuperFIT achieved by the above different methods are contrasted in Tab 1, which showed that the values of the torsion angles of rotatable bonds as well as the distances between each key moiety for interacting with  $\delta$ OR are very similar. These facts proved that, not only did the

Tab 1. Bioactive conformations and geometric parameters of (3R,4S)-SuperFIT<sup>a</sup>.

Conforms	DISCO <sup>a</sup>	Extracted <sup>b</sup>	Sys-Dock <sup>c</sup>
$\varphi_{19-1-2-3}^{\circ}$	-178.7	-155.1	-168.3
$\varphi_{1-2-3-8}^{\circ}$	-88.8	-62.8	-72.1
$\varphi_{7-6-9-13}^{\circ}$	125.2	123.4	123.7
$\varphi_{12-10-9-6}^{\circ}$	179.4	176.0	175.4
$\varphi_{25-12-10-9}^{\circ}$	-176.5	-175.0	-176.8
$\varphi_{6-9-13-18}^{\circ}$	89.4	106.0	-72.2
$\varphi_{24-19-1-2}^{\circ}$	-89.5	35.0	62.4
$\varphi_{27-26-23-21}^{\circ}$	179.9	6.9	-5.5
$d_{26-3}(\text{nm})$	0.7844	0.7787	0.7961
$d_{26-11}(\text{nm})$	1.2831	1.2927	1.2974
$d_{26-B}(\text{nm})$	1.3327	1.3262	1.3649
$d_{28-3}(\text{nm})$	0.9878	1.0191	1.0252
$d_{28-11}(\text{nm})$	1.4356	1.4976	1.4811
$d_{28-B}(\text{nm})$	1.5648	1.5930	1.6159
$d_{3-11}(\text{nm})$	0.5308	0.5356	0.5360
$d_{3-B}(\text{nm})$	0.5894	0.5932	0.5989
$d_{11-B}(\text{nm})$	0.4871	0.4895	0.4892

<sup>a</sup> $\varphi_{i-j-k-l}$ (degree) is the torsion angle between i, j, k, and l atom;  $d_{m-n}$ (nm) is the distance between m and n atom, 2 key moieties of the ligand for interacting with  $\delta$  opioid receptor; <sup>b</sup>The bioactive conformation used to docking, which was obtained by multi-conformational search and DISCO method; <sup>c</sup>The bioactive conformation extracted from the complex model; <sup>d</sup>The bioactive conformation achieved by Sys-Docking method.

initial conformation of the ligand used in docking be reasonable, but also  $\delta$ OR and its complex model with (3R, 4S)-SuperFIT had certain reliability. More importantly, this bioactive conformation may be chosen as the starting conformation of ligand for rational drug design.

**Comparing  $\delta$ OR model to  $\mu$ OR model** It is well known that there are at least 3 major classes of opioid receptors, designated  $\mu$ ,  $\delta$ ,  $\kappa$ , whose amino acid sequences had been determined from their cDNA sequences, respectively<sup>[2,11]</sup>.

In our previous study, the 3D structural model of  $\mu$ OR was built up<sup>[12]</sup>. The alignment of the amino acid sequences of  $\mu$ OR and  $\delta$ OR revealed 61 % identity. On the basis of the alignment of bRh and  $\mu$ OR as well as that of  $\mu$ OR and  $\delta$ OR, the alignment of each TM region between bRh and  $\delta$ OR was obtained indirectly, which was the same as that listed in Fig 2. This result is reasonable and makes it possible to compare the ligand-binding sites of  $\delta$ OR to those of  $\mu$ OR. The similarities and differences between the  $\delta$ OR and the  $\mu$ OR model are shown in Tab 2.

To elucidate the selectivity of SuperFIT for  $\delta$ OR, we also docked (3R,4S)-SuperFIT into  $\mu$ OR model (Fig 4). Comparing the complex of (3R, 4S)-SuperFIT with  $\delta$ OR to its complex with  $\mu$ OR, we found that, in (3R,4S)-SuperFIT- $\mu$ OR complex model, there were no the binding sites to interact with the isothiocyano group, *ie*, the residues corresponding to Ser106, Phe104, Tyr308, and Pro315 in the (3R, 4S)-SuperFIT- $\delta$ OR complex model. This might be one of the reason of the  $\delta$ -selectivity of SuperFIT.

We also contrasted the (3R, 4S)-3-MF- $\mu$ OR complex model<sup>[12]</sup> (Fig 4) with the (3R, 4S)-SuperFIT- $\delta$ OR complex model and found that there were some evident differences between them. Briefly, the main differences are as the following:

(1) In the (3R,4S)-SuperFIT- $\delta$ OR complex, there were some interactions between the isothiocyano group of the ligand and Phe104, Tyr308 and Pro315 as well as Ser106; whereas these interactions were not existed in the (3R,4S)-3-MF- $\mu$ OR complex, due to the lack of isothiocyano group in the ligand.

(2) The ligand's conformations were very

Tab 2. Similarities and differences between  $\delta$ OR and  $\mu$ OR.

$\delta$ OR	$\mu$ OR
Asp128 (TM3) <sup>a</sup> formed the potent electrostatic and hydrogen-binding interactions with the protonated nitrogen on piperidine of (3R,4S)-SuperFIT.	Asp147 (TM3) <sup>a</sup> formed the potent electrostatic and hydrogen-binding interactions with the protonated nitrogen on piperidine of (3R,4S)-3-MF.
The interactions between His278 (TM6) <sup>a</sup> and the carbonyl oxygen in 4-phenylpropanamide of (3R, 4S)-SuperFIT are exceedingly weaker, even partly disappeared.	His297 (TM6) <sup>a</sup> formed the weak electrostatic and hydrogen-binding interactions with the carbonyl oxygen in 4-phenylpropanamide of (3R, 4S)-3-MF.
Ser106 (TM2) formed the electrostatic interaction with the N atom of isothiocyano group of (3R,4S)-SuperFIT.	
Phe104 (TM2), Tyr308 (TM7) <sup>a</sup> , and Pro315 (TM7) formed one small hydrophobic pocket to interact with the S atom of isothiocyano group of (3R, 4S)-SuperFIT.	Tyr326 (TM7) <sup>a</sup> formed the $\pi - \pi$ interactions with the $\beta$ -phenyl ring of (3R4S)-3-MF.
Leu125 (TM3) <sup>b</sup> , Tyr129 (TM3) <sup>a</sup> , and Val181 (TM4) <sup>b</sup> formed one small hydrophobic pocket to interact with 3-methyl of (3R, 4S)-SuperFIT, which has steric selectivity.	Ile144 (TM3) <sup>b</sup> , Tyr148 (TM3) <sup>a</sup> , and Leu200 (TM4) <sup>b</sup> formed one small hydrophobic pocket to interact with 3-methyl of (3R, 4S)-3-MF, which has obvious steric selectivity.
Trp173 (TM4) <sup>a</sup> and Tyr129 (TM3) were nearly unsuitable to the $\pi - \pi$ interactions with the phenyl ring in 4-phenylpropanamide of (3R,4S)-SuperFIT.	Trp192 (TM4) <sup>a</sup> and Tyr148 formed the $\pi - \pi$ interactions with the phenyl ring in 4-phenylpropanamide of (3R,4S)-3-MF.

<sup>a</sup>The same amino acid; <sup>b</sup>Different amino acid residues in the alignment of TM regions between  $\delta$ OR and  $\mu$ OR.

dissimilar in the above 2 complex models, especially the conformations of 4-phenylpropanamide and  $\beta$ -aromatic ring. In (3R,4S)-3-MF- $\mu$ OR complex model, (I) the carbonyl oxygen of the ligand was closer to His297, which was suitable to the weak electrostatic and hydrogen-binding interactions between them; (II) the phenyl ring in 4-phenylpropanamide of the ligand was inserted between Tyr148 and Trp192, which resulted in the  $\pi - \pi$  interactions between them; (III) the  $\beta$ -phenyl

ring was nearly parallel to the aromatic ring of Tyr326, which was benefit to the  $\pi - \pi$  interactions between them. However, the similar interactions in (3R,4S)-SuperFIT- $\delta$ OR complex model became extremely weaker, even partly disappeared, because the conformations of 4-phenylpropanamide and  $\beta$ -phenyl ring of the ligand were nearly unsuitable to the geometric arrangement of corresponding amino residues.

Summarily, the amino acid residues Phe104 (TM2), Tyr308 (TM7), Pro315 (TM7), and Ser106 (TM2) of  $\delta$ OR probably are the key ligand-binding sites to the  $\delta$ -selectivity of (3R, 4S)-SuperFIT; whereas the residues His297 (TM6), Tyr148 (TM3), Trp192 (TM4), and Tyr326 (TM7) of  $\mu$ OR might be the significant ligand-binding sites to the  $\mu$ -selectivity of (3R,4S)-3-MF.

In conclusion, the present  $\delta$ OR model and its complex model with (3R, 4S)-SuperFIT are preliminary, and further modification is necessary for quantitative analysis of the receptor-ligand interaction. It is, however, at least qualitatively useful for comprehending the interaction mechanism between  $\delta$ OR and its ligand and for designing novel  $\delta$ -selective ligand.

REFERENCES

- 1 Wang ZX. Studies on opioid sub-receptor selective ligands. II Synthesis of analogues of  $\delta$ -selective irreversible inhibitors FIT and SuperFIT [dissertation]. Shanghai: Shanghai Institute of Materia Medica, 1994.
- 2 Yasuda K, Raynot K, Kong H, Breder CD, Takeda J, Reisine T, *et al.* Cloning and functional comparison of  $\kappa$  and  $\delta$  opioid receptors from mouse brain. *Proc Natl Acad USA* 1993; **90**: 6736-40.
- 3 SYBYL [computer program], version 6.2. St Louis (MO): Tripos Associates Inc, 1995.
- 4 Cromet P, Sander C, Vriend G. Modeling of transmembrane seven helix bundles. *Protein Eng* 1993; **6**: 59-64
- 5 Hunderson R, Baldwin JM, Ceska TA, Zernlin F, Beckmann E, Downing KH. Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. *J Mol Biol* 1990; **213**: 899-929.

- 6 Findlay JBC, Pappun DJC. The opsin family of proteins. *Biochem J* 1986; **238**: 625-42.
- 7 Baldwin JM. The probable arrangement of the helices in G protein-coupled receptors. *EMBO J* 1993; **12**: 1693-703.
- 8 Strader CD, Sigal IS, Dixon RAF. Structural basis of  $\beta$ -adrenergic receptor function. *FASEB J* 1989; **3**: 1825-32
- 9 Savarese TM, Fraser CM. *In vitro* mutagenesis and the search for structure-function relationship among G protein-coupled receptors. *Biochem J* 1992; **283**: 1-19
- 10 Uhl GR, Childers S, Pasternak G. An opiate-receptor gene family reunion. *Trends Neurosci* 1994; **17**: 89-93.
- 11 Chen Y, Mestek A, Liu J, Hurley JA, Yu L. Molecular cloning and functional expression of a  $\mu$ -opioid receptor from rat brain. *Mol Pharmacol* 1993; **44**: 8-12.
- 12 Rong SB, Zhu YC, Jiang HL, Zhao SR, Wang QM, Chi ZQ, *et al.* Molecular modeling of  $\mu$  opioid receptor and the receptor-ligand interaction. *Acta Pharmacol Sin* 1997; **18**: in press

219-224

$\delta$ 阿片受体与异硫氰基 3-甲基芬太尼相互作用的分子模拟

戎锁宝, 蒋华良, 池志强, 陈凯先, 朱友成, 嵇汝运

(中国科学院上海药物研究所, 上海 200031, 中国)

关键词  $\delta$ 阿片受体; 分子模型; 结合位点; 配基; 芬太尼

目的: 构建  $\delta$ 阿片受体( $\delta$ OR)结构模型并研究它与异硫氰基 3-甲基芬太尼(SuperFIT)的相互作用. 方法: 以细菌视紫红质为模板, 模拟  $\delta$ OR 的结构, 并将 SuperFIT 对接于其内. 结果: 得到  $\delta$ OR-(3R,4S)-SuperFIT 作用模型; 其中, 重要结合位点可能是 Asp128, Ser106, Phe104, Tyr308 及 Pro315. Asp128 与配基哌啶环上质子化氮原子形成强的静电和氢键相互作用; Ser106 与配基异硫氰基 N 原子形成静电作用; Phe104, Tyr308 及 Pro315 与异硫氰基 S 原子形成疏水作用. 结论: Phe104, Tyr308, Pro315 及 Ser106 对配基的  $\delta$  选择性极重要, 这将有利于设计新的  $\delta$  选择性配基.